Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
0PQ:FRA
ProQR Therapeutics NV
1,30 €
-0,31%
(-0,0040) 1D
30 apr, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 0PQ...
Açın
1,30 €
High
1,30 €
Low
1,30 €
Mkt. cap
163,31 mln
Avg. vol.
239,00
Volume
0,00
52-wk high
2,56 €
52-wk low
1,14 €
No. of employees
187
News stories
From sources across the web
Profile
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. Wikipedia
About ProQR Therapeutics NV
CEODaniel A. de Boer
Employees187
Founded2012
Headquarters-
Sector-
Websiteproqr.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
4,74 mln
3,98 mln
2,92 mln
4,72 mln
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12,32 mln
11,41 mln
11,08 mln
9,92 mln
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,23 mln
4,82 mln
3,12 mln
3,89 mln
Operating expense
15,56 mln
16,22 mln
14,20 mln
13,81 mln
Total operating expenses
15,56 mln
16,22 mln
14,20 mln
13,81 mln
Operating income
-10,82 mln
-12,25 mln
-11,28 mln
-9,10 mln
Other non operating income
282,00K
-104,00K
-2,00K
59,00K
EBT including unusual items
-10,08 mln
-12,16 mln
-11,01 mln
-8,92 mln
EBT excluding unusual items
-10,08 mln
-12,16 mln
-11,01 mln
-8,92 mln
Income tax expense
-
18,00K
-
1,00K
Effective tax rate
-
-0,15%
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-10,08 mln
-12,18 mln
-11,01 mln
-8,92 mln
Net profit margin
-212,59%
-306,39%
-377,56%
-189,14%
Earnings per share
-
-
-
-
Interest and investment income
455,00K
192,00K
280,00K
1,41 mln
Interest expense
-
-
-
-929,00K
Net interest expenses
455,00K
192,00K
280,00K
477,00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,14 mln
-11,57 mln
-10,61 mln
-8,87 mln
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer